ArticleJournal for immunotherapy of cancer2019

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Elizabeth I Buchbinder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.